SANOFI ADR

NASDAQ: SNY (Sanofi)

最近更新时间: 15小时之前

49.53

0.63 (1.29%)

前收盘价格 48.90
收盘价格 49.71
成交量 2,342,411
平均成交量 (3个月) 2,918,939
市值 120,898,920,448
市盈率 (P/E TTM) 16.24
预期市盈率 (P/E Forward) 9.97
价格/销量 (P/S) 2.28
股市价格/股市净资产 (P/B) 1.41
52周波幅
44.62 (-9%) — 60.12 (21%)
利润日期 29 Jan 2026
股息率 (DY TTM) 4.47%
营业毛利率 13.95%
营业利益率 (TTM) 20.78%
稀释每股收益 (EPS TTM) 2.94
季度收入增长率 (YOY) -4.60%
季度盈利增长率 (YOY) 65.20%
总债务/股东权益 (D/E MRQ) 23.01%
流动比率 (MRQ) 1.46
营业现金流 (OCF TTM) 9.08 B
杠杆自由现金流 (LFCF TTM) -4.94 B
资产报酬率 (ROA TTM) 4.28%
股东权益报酬率 (ROE TTM) 7.30%

市场趋势

短期 中期
行业 Drug Manufacturers - General (US) 看涨 看跌
Drug Manufacturers - General (全球的) 看涨 看跌
股票 Sanofi 看跌 看跌

AIStockmoo 评分

-0.5
分析师共识 -0.5
内部交易活动 NA
价格波动 -1.0
技术平均移动指标 0.0
技术振荡指标 -0.5
平均 -0.50

相关股票

股票 市值 DY P/E(TTM) P/B
SNY 121 B 4.47% 16.24 1.41
AZN 282 B 1.72% 30.18 6.09
AMGN 182 B 2.82% 26.13 19.34
GILD 154 B 2.55% 19.24 7.32
GRFS 7 B 1.96% 14.05 1.00
BIIB 27 B - 16.61 1.42

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

部门 Healthcare
行业 Drug Manufacturers - General
投资方式 Large Core
机构持股比例 10.49%

所有权

姓名 日期 持有股份
Mondrian Investment Partners Ltd 30 Sep 2025 3,638,606
52周波幅
44.62 (-9%) — 60.12 (21%)
58.00 (17.10%)
总计 1 购买
公司 日期 目标价格 调整类型 价格@调整类型
Morgan Stanley 08 Sep 2025 58.00 (17.10%) 购买 46.80

该时间范围内无数据。

日期 类型 细节
04 Dec 2025 公告 Press Release: Sanofi completes acquisition of Vicebio
04 Dec 2025 公告 Press Release: Sanofi completes acquisition of Vicebio
25 Nov 2025 公告 Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
25 Nov 2025 公告 Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
18 Nov 2025 公告 Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors
14 Nov 2025 公告 Press Release: Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes
14 Nov 2025 公告 Press Release: Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes
13 Nov 2025 公告 Sanofi: Information concerning the total number of voting rights and shares – October 2025
07 Nov 2025 公告 Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
07 Nov 2025 公告 Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
28 Oct 2025 公告 Press release: Sanofi successfully prices USD 3 billion of bond issue
28 Oct 2025 公告 Press release: Sanofi successfully prices USD 3 billion of bond issue
27 Oct 2025 公告 UPDATE - Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey
24 Oct 2025 公告 Press release: Q3: continued sales and earnings progress
24 Oct 2025 公告 Press release: Q3: continued sales and earnings progress
23 Oct 2025 公告 Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey
22 Oct 2025 公告 Press Release: Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study
22 Oct 2025 公告 Press Release: Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study
20 Oct 2025 公告 Press Release: Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program
20 Oct 2025 公告 Press Release: Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program
20 Oct 2025 公告 Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
20 Oct 2025 公告 Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
20 Oct 2025 公告 Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
20 Oct 2025 公告 Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
20 Oct 2025 公告 Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
17 Oct 2025 公告 Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease
17 Oct 2025 公告 Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease
17 Oct 2025 公告 Press Release: Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia
17 Oct 2025 公告 Press Release: Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia
16 Oct 2025 公告 EVOQ Therapeutics Announces Collaboration and License Agreement with Sanofi
14 Oct 2025 公告 Sanofi: Information concerning the total number of voting rights and shares - September 2025
08 Oct 2025 公告 Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors
08 Oct 2025 公告 Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors
08 Oct 2025 公告 Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors
02 Oct 2025 公告 Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes
26 Sep 2025 公告 Sanofi expands patient affordability program by offering access to all its insulins for $35 per month in the US
24 Sep 2025 公告 Press Release: Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation
24 Sep 2025 公告 Press Release: Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation
24 Sep 2025 公告 Press release: Availability of the Q3 2025 Aide mémoire
24 Sep 2025 公告 Press release: Availability of the Q3 2025 Aide mémoire
23 Sep 2025 公告 Press Release: Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1
23 Sep 2025 公告 Press Release: Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1
22 Sep 2025 公告 Press Release: Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis
22 Sep 2025 公告 Press Release: Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis
22 Sep 2025 公告 Press Release: Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
22 Sep 2025 公告 Press Release: Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
17 Sep 2025 公告 Press Release: EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
17 Sep 2025 公告 Press Release: EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
12 Sep 2025 公告 Sanofi: Information concerning the total number of voting rights and shares - August 2025
11 Sep 2025 公告 Press Release: Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration
11 Sep 2025 公告 Press Release: Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration
10 Sep 2025 公告 Mandy Moore and Celebrity Mom Squad join Sanofi to help protect babies from RSV with BEYFORTUS®
10 Sep 2025 公告 Press Release: Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes
10 Sep 2025 公告 Press Release: Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes
显示更多
股息率 (DY TTM) 4.47%
5年平均股息收益率 4.78%
股息支付比率 75.37%
预计下次股息支付 Jun 2026
除息日 公告日期 支付日期 详情
09 May 2025 15 Apr 2025 12 Jun 2025 2.212154 现金
09 May 2024 26 Mar 2024 06 Jun 2024 2.037356 现金
09 May 2024 26 Mar 2024 06 Jun 2024 2.0369079 现金
30 May 2023 - 23 Jun 2023 1.9000852 现金
26 May 2022 - 27 Jun 2022 0.2971788 现金
04 May 2022 20 Apr 2022 31 May 2022 1.7967514 现金
03 May 2021 23 Mar 2021 26 May 2021 1.906064 现金
30 Apr 2020 05 Mar 2020 26 May 2020 1.6993994 现金
07 May 2019 - 31 May 2019 1.722322 现金
09 May 2018 07 Feb 2018 04 Jun 2018 1.860874 现金
11 May 2017 16 Feb 2017 07 Jun 2017 1.577088 现金
05 May 2016 19 Feb 2016 01 Jun 2016 1.630252 现金
06 May 2015 25 Feb 2015 02 Jun 2015 1.618087 现金
17 May 2010 12 Feb 2010 14 Jun 2010 1.62732 现金
04 Jun 2007 05 Mar 2007 03 Jul 2007 1.14537 现金
02 Jun 2006 06 Mar 2006 03 Jul 2006 0.912 现金
02 Jun 2005 01 Mar 2005 01 Jul 2005 0.7993 现金
显示更多

每年股息收益率

年份 每年总股息 ($) 频率/年份 收益率 %
2025 2.21 1 4.47
2024 4.07 2 8.45
2023 1.90 1 3.82
2022 2.09 2 4.32
2021 1.91 1 3.81
2020 1.70 1 3.50
2019 1.72 1 3.43
2018 1.86 1 4.29
2017 1.58 1 3.67
2016 1.63 1 4.03
2015 1.62 1 3.79
2010 1.63 1 5.05
2007 1.15 1 2.52
2006 0.912 1 1.98
2005 0.799 1 1.82
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票